Genomics and clinical trial support for ovarian cancer
There are over 600 live clinical trials for cancer in the UK today. Finding the right clinical trial can be overwhelming. The jargon is heavy, criteria are strict, and doctors rarely have time to explore every option. RareCan provides a dedicated, expert service to cut through the noise.
Our team does the heavy lifting by:
- Navigating complex trial databases on your behalf.
- Creating a personalised shortlist of potential treatment trial options.
- Working alongside your clinical team to support the referral process.
We look both at trials specifically for people with ovarian cancer, and those that target specific features (such as genetic changes) across a range of cancers.
If you would like support with understanding, finding and accessing clinical trials, please choose the level of support that you would like to start with. We look forward to helping you.
Understand your clinical trial options
Talk to one of our experienced Clinical Trial Navigators- 30 minute call with an experienced Trial Navigator
- Review your current situation
- Explanation of UK cancer trials
- £50 credit towards Personalised Report or InsightDecode
RareCan has over 100 members with ovarian cancer
Explore our liquid biopsy genomic tests
Insight CSB - Comprehensive Genomic Profiling of Solid Tumours from Blood
What it is:
The CSB test analyses a broad range of cancer-related genes from a blood sample to provide a detailed understanding of your tumour biology – with results written for people, not just specialists.
What it is for:
Designed for people who want the fullest possible insight, particularly when:
- Standard treatment options have been exhausted
- You want to explore what else might exist beyond routine care
- You want a report you can actually use in conversations about next steps
Why it is different:
- Broader gene coverage than other leading market tests
- UK-focused clinical trial matching, explained in context
- A clear, human-readable summary – not just technical findings
Genes included:
The CSB panel analyses 523 genes for SNVs/InDels, 59 genes for CNVs, and 23 genes for fusions, covering the most frequently referenced and clinically relevant in rarer solid tumours, including TP53, BRCA1/2, KRAS, EGFR, BRAF, HER2, ALK, PIK3CA, MMR genes, NTRK and more.
Additional biomarkers:
- Microsatellite instability (MSI), a feature of how DNA repair works
- Tumour mutational burden (TMB), a measure of how many mutations are present
- Tumour fraction (TFx), an estimate of the proportion of the cell-free DNA arising from the tumour
Price: £3,250
Get more information about the Insight CSB test
Book a free call to find out whether the Insight CSB is right for you
Ready to book an Insight CSB test? Click here to order a test today
Insight TSB - Targeted Genomic Profiling of Solid Tumours from Blood
What it is:
The TSB test analyses a targeted set of cancer-related genes from a blood sample, providing clear insight into tumour changes over time, with the same emphasis on clarity and UK trial context.
What it is for:
Designed for people who:
- Wish to track disease progression or molecular changes over time, or
- Want more affordable access to key tumour genomics to explore what else might exist beyond routine care
Why it is different:
- Broader coverage and better sensitivity than comparable tests
- UK-focused clinical trial matching, explained in context
- A clear, human-readable summary – not just technical findings
Genes included:
The TSB test detects 118 cancer-related genes, covering the most frequently referenced and clinically relevant in rarer solid tumours, including TP53, BRCA1/2, KRAS, EGFR, BRAF, HER2, ALK, PIK3CA, MMR genes, NTRK and more.
Additional biomarker:
- Tumour fraction (TFx), an estimate of the proportion of the cell-free DNA arising from the tumour
Price: £2,200
Get more information about the Insight TSB test
Book a free call to find out whether the Insight TSB is right for you
Ready to book an Insight TSB test? Click here to order a test today
About our clinically validated cancer biomarkers
Circulating Tumour DNA (ctDNA)
ctDNA enables genetic profiling of your ovarian cancer without invasive tissue biopsies. Recent clinical reviews show that liquid biopsies can identify actionable mutations driving tumour growth and may outperform traditional CA-125 testing in tracking disease evolution and monitoring for resistance.
Tumour Mutational Burden (TMB)
TMB calculates the total number of mutations present within your tumour. In ovarian cancer, discovering a high mutational burden provides prognostic information and is a key factor in predicting how strongly your immune system will respond to emerging targeted treatments and clinical trials.
Microsatellite Instability (MSI)
While standard NHS panels rarely test for it, measuring MSI is important for ovarian cancer patients facing treatment resistance. A high MSI score acts as a predictive biomarker indicating that a patient may be a candidate for novel immunotherapies like Pembrolizumab.
Tumour Fraction (TFx) Estimates
Your report includes a Tumour Fraction estimate, which calculates the proportion of the cell-free DNA isolated in your blood sample that is tumour DNA. Accurately measuring this is emerging as a powerful non-invasive biomarker to assess overall tumour burden and monitor disease progression.
We are proud to partner with Ovacome Ovarian Cancer
We are delighted to partner with Ovacome, a charity that has been providing information and support to those affected by ovarian cancers since 1996. Founded by ovarian cancer survivors, Ovacome is at the heart of the ovarian cancer community and is working directly to meet the needs of those affected by the disease. Growing our own ovarian cancer community will allow us to build a resource for researchers which will make it easier for them to find participants for clinical trials and other research.
Summary of Ovarian Cancer
What is Ovarian Cancer?
Ovarian cancer is when abnormal cells in one or both ovaries begin to grow and divide in an uncontrolled way. Most of these cancers start in the cells covering the ovary (epithelial cells), although rarer types begin in the egg-producing or hormone-producing parts. These cells may invade nearby tissues or organs and can spread to other areas of the body if left untreated.
How rare is it?
In the UK around 7,600 new cases of ovarian cancer are diagnosed each year (2017-2019), which is about 2 % of all new cancers and makes it the 6th most common cancer in women. Mortality is around 3,900 deaths annually (2021-2023) and the survival for ten years or more is roughly 39.3 %. The incidence is projected to rise to about 9,400 new cases per year in the UK by around 2038-2040.
Who does it affect?
The risk of developing ovarian cancer increases with age, with incidence rates highest in women aged 75-79. Incidence rates are lower in Asian and Black ethnic groups compared with White ethnic groups in England.
How we can help you

Clinical Trials
Helping you understand, find and navigate clinical trials as potential treatment options

Genetic Testing
Genomic testing designed for people living with a cancer diagnosis who want to understand their cancer in more detail to support decision making.
Frequently asked questions
What is a clinical trial?
A clinical trial is a type of research study that tests new medicines, treatments, or approaches to care. The goal is to find out if they are safe and effective for people.
Who can take part in a clinical trial?
Each trial has specific rules called “eligibility criteria.” These might include age, type of condition, stage of illness, or previous treatments. These criteria can be very detailed, meaning that even if a trial looks suitable for you on the face of it, you may not be able to take part due to some specific inclusion or exclusion criteria. Clinical trials also sometimes limit access to patients from particular locations and/or are open to a limited number of patients.
Do I have to pay to take part in a clinical trial?
Most trials are free to take part in. The study team usually covers the cost of the treatment being tested. Sometimes travel expenses may also be reimbursed.
How does RareCan make finding trials easier?
Publicly available clinical trial data is often complex, unreliable, or out of date. We maintain our own highly curated database of UK treatment trials. Instead of you spending hours deciphering medical jargon, our expert team does the heavy lifting. We review the complex eligibility criteria, create a shortlist of trials tailored to your diagnosis, and support you and your clinical team in making referrals. We also update your report periodically as your situation or the trial landscape changes.
When is a trial likely to be an option for me?
Clinical trials are usually considered when there is no standard treatment available. This can happen when you are first diagnosed (particularly with a later-stage or rare cancer) but is most common after you have already received the standard-of-care treatments for your cancer.
If I use RareCan’s trial service, am I committing to join a trial?
No. RareCan helps you find information about potentially suitable trials. You should always talk to your clinical team about whether any of the trials identified might be suitable, and your doctor will make a referral if appropriate. The trial team will then talk you through the trial in detail before you decide whether you would like to join or not. You will then go through detailed screening to see if you are suitable for the trial. Whether you join a trial is always your choice.
Will I definitely get the new treatment?
Not always. Some trials randomly assign participants to receive either the new treatment or the best available standard treatment. This helps researchers make fair comparisons.
Is joining a clinical trial safe?
Trials follow strict rules to protect participants. Safety is closely monitored, but all treatments can have risks. The research team will explain these clearly before you decide.
If I pay for a Personalised Trial Report or InsightDecode, am I guaranteed a spot on a trial?
No, we cannot guarantee you will be enrolled in a trial. We work alongside you and your clinical team to find the best potential options. However, trials have very strict and complex eligibility criteria. Some of these criteria can only be assessed during medical screening at the trial site itself. Additionally, trials have limited spaces, meaning they may close enrollment even if you are a perfect match.
Do RareCan reports contain information about trials outside the UK?
No. At RareCan we are focused on helping you find treatment options in the UK. We will be extending the service to residents of other countries soon, and will start offering reports that include international trials in due course, but currently we are focused on providing high quality, personalised information about treatment trials in the UK only.
Do RareCan reports contain every clinical trial that might be suitable for me?
Not every trial. Our reports focus on treatment trials and aim to highlight the most relevant options for you. There isn’t a single perfect, complete source of trial information, so while we work hard to keep our database up to date, it may not include every possible trial. Our reports are designed to support you and your clinical team in exploring potential next treatment options, but they should not be seen as a complete list.
What is the difference between the Personalised Trial Report and the InsightDecode service?
The Personalised Trial Report searches for trials based on your general clinical history and cancer type. The InsightDecode service goes a step further by using your existing genetic test results (such as a FoundationOne or Guardant360 report). We translate that complex genomic data into plain English and use your specific genetic mutations (biomarkers) to find highly targeted, precision medicine trials that standard searches might miss.
How do genetic tests help identify clinical trials?
Many modern cancer treatments are “targeted therapies.” This means the drug is designed to attack a specific genetic alteration driving your tumour’s growth. A genetic test maps out the DNA of your cancer. By knowing your exact genetic profile, we may be able to match you to cutting-edge clinical trials testing new drugs against those specific mutations.
Do I need to have a genetic test before I can use RareCan?
No. We can conduct a comprehensive search using your standard clinical history through our Personalised Trial Report. However, having genetic data often opens the door to more specific targeted therapy trials. If you haven’t had a genetic test yet, you can explore our private Insight genomic testing services to get a detailed profile of your tumour.
I already have a complex genomic report from my doctor. Can you help me understand it?
Yes. If you already have a genetic test report but aren’t sure what it means for your treatment options, our InsightDecode service is designed exactly for this. We will translate the heavy scientific jargon into a clear summary and use the data to search for targeted trials that match your genetic profile.
Supported by






Regulatory complaince



RareCan has over 3,000 members, here’s what some of them say.
The voices and experiences from our RareCan members, shared to help others on their own cancer journey.

“I joined RareCan to support research into my extremely rare and highly aggressive subtype of uterine cancer.”
— Lindy
RareCan Member

“I joined RareCan to get action and support and research on rare cancers”
— Steve
RareCan Member

“I joined RareCan because they have the solution to the challenges faced within rare cancer research.”
— Dave
RareCan Member

“I joined RareCan as it may help other people in the future.”
— Wayne
RareCan Member

“If my husband was alive today, he would encourage people to take part in research as you never know if you will ever need it in the future.”




